Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Initiation of coverage by Edison Investment Research



Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces that Edison Investment Research, an international leading independent investment research company, has just initiated coverage of Quantum Genomics with an initiation note entitled « The next generation of cardiac drugs ».


Edison's initiation note is available on the company's website, www.quantum-genomics.com, in the Equity research section of the Investors tab, which already includes Aurgalys and Invest Securities' ones.


Click here to download Edison's initiation note








CONTACTS

Quantum Genomics


Lionel Ségard

Chairman & Chief Executive Officer

+33 1 85 34 77 77

 

Quantum Genomics

Marc Karako

CFO – Investor Relations

+33 1 85 34 77 75

[email protected]

 

ACTUS finance & communication (Europe)

Jean-Michel Marmillon

Press Relations

+33 1 53 67 36 73 / [email protected]

 

The Ruth Group (U.S.)

Lee Roth / Kirsten Thomas

Investor / Public Relations

+1 646-536-7012 / +1 508-280-6592



 








ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.





Regulated information

News releases under ongoing reporting obligations:

- other releases

Full and original press release in PDF:


https://www.actusnews.com/documents_communiques/ACTUS-0-46542-QUANTUM_PR_Edison-coverage_20161129_EN.pdf


Receive by email the next press releases of the company by registering on
www.actusnews.com, it's free



Source: Actusnews

Quantum Genomics S.A. Aktie

0,068 €
1,64 %
Heute erlebt Quantum Genomics S.A. einen merklichen Gewinn von 1,64 %.

Like: 0
Teilen

Kommentare